Homologous Recombination News and Research

RSS

Conceptual framework to examine the patterns of copy number alterations in human cancer

A new study published in Nature presented a conceptual framework to examine the patterns of copy number alterations in human cancer.

17 Jun 2022

An Ad5 vectored COVID vaccine expressing an S1-N fusion protein

In a recent study posted to the bioRxiv* preprint server, researchers characterized the development of multiple adenovirus-vectored and subunit recombinant protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates.

12 May 2022

Research describes how DNA damage can affect neural health and function

A new research paper in the journal EMBO Reports describes how DNA damage can affect neural health and function.

12 May 2022

Study suggests SARS-CoV-2 is undergoing evolutionary changes at the functional RNA level in addition to the amino acid level

Researchers demonstrated SARS-CoV-2 evolution at the transcriptional level.

22 Apr 2022

Research using kidney organoids may lead to new targets to help prevent or treat CKD

To a certain extent, kidneys have the capacity to repair themselves after being injured, but a switch can occur from such intrinsic repair to incomplete repair that leads to irreversible damage and chronic kidney disease (CKD).

12 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

HRR mutational status associated with survival outcomes in recurrent platinum-sensitive ovarian cancer

Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer in March 2022.

19 Mar 2022

Study demonstrates that TMPRSS2, which is key to SARS-CoV-2 cell entry, is a tumor suppressor

The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of a new study.

23 Feb 2022

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Uppsala researchers find solution to long-standing biological search enigma

How the cell can mend broken DNA using another DNA copy as template has puzzled researchers for years. How is it possible to find the correct sequences in the busy interior of the cell? Researchers from Uppsala university have now discovered the solution; it is easier to find a rope than a ball if you are blindfolded.

1 Sep 2021

How replication and recombination contribute to emergence of SARS-CoV-2 variants

The coronavirus disease 2019 (COVID-19) pandemic has been caused by the rapid outbreak of a novel coronavirus, namely, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 was first reported in late December 2019 in Wuhan, China. Since then, the virus has already claimed more than 4.3 million lives worldwide.

13 Aug 2021

Start codon disruption with CRISPR-Cas9 gene editing prevents Fuchs’ corneal dystrophy in mice

In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' corneal dystrophy in mice.

3 Aug 2021

Researchers develop a transferrable and integrative type I CRISPR-based platform to edit superbugs

A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, reported the development of a transferrable and integrative type I CRISPR-based platform.

23 Jul 2021

Researchers define genetic landscape of uterine leiomyosarcomas

In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).

6 Apr 2021

Where might future novel coronaviruses come from?

The researchers predicted many more associations between coronaviruses and host species than have been observed to date. They also predicted 30 times more potential recombination hosts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Feb 2021

Scientists examine DNA repair pathways and their impact on cancer evolution

DNA repair pathways exist to correct molecular damage caused by internal and external factors. However, any damage to these pathways can result in the creation of tumors and specific types of cancers.

17 Feb 2021

Discovery about DNA repair enzyme could lead to new treatments for certain cancers

Researchers at the Francis Crick Institute have found a new way to prevent some tumours from repairing their own DNA, a function that is essential for cancer cell survival.

16 Dec 2020

Study: Tumors with high TMB tend to respond better to immune checkpoint inhibitors

Treatments that harness the immune system to fight cancer have greatly improved outcomes for some people with cancer. Scientists are learning more about why some people respond much better than others to these drugs.

2 Dec 2020

Biomarkers that are predictive of clinical benefit in Trop-2-expressing triple-negative breast cancer

Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.

3 Nov 2020

PROfound phase III results offer new targeted treatment for metastatic prostate cancer

Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.

21 Sep 2020